Search results for "neuro-oncology"

showing 6 items of 6 documents

BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOB…

2021

Abstract BACKGROUND The CeTeG/NOA-09 trial showed that lomustine/temozolomide chemotherapy prolongs survival for newly diagnosed MGMT-methylated glioblastoma patients. Previous reports on temozolomide monotherapy suggested, that the survival benefit of temozolomide in MGMT-methylated tumors may be restricted to the RTK II methylation subgroup and absent in RTK I and MES subgroups. To identify patients with a particularly strong benefit from CCNU/TMZ, we explored the association of methylation subgroups with outcome after lomustine/temozolomide therapy. METHODS All patients from the CeTeG/NOA-09 trial with sufficiently available tumor tissue (n = 98) underwent 850K methylation array analysis…

Cancer ResearchCombination therapybusiness.industryMedizinPromoterLomustine26th Annual Meeting & Education Day of the Society for Neuro-Oncologymedicine.diseaseSurvival benefitOncologyDNA methylationmedicineCancer researchNeurology (clinical)Temozolomidbusinessmedicine.drugGlioblastomaNeuro-Oncology
researchProduct

Health status, health-related quality of life, and socioeconomic outcome in childhood brain tumor survivors: a German cohort study

2019

Abstract Background With rising numbers of childhood cancer survivors, somatic and socioeconomic outcome as well as health-related quality of life (QoL) gain increasing relevance. Based on the first nationwide German Survey on Life Situation, State of Health, and Quality of Life of Childhood Cancer Survivors, the VIVE survey, we report the outcome of survivors of childhood brain tumors localized in the posterior fossa. Methods Two hundred seventy participants with a median follow-up period of 21.9 years completed a questionnaire on socioeconomic and somatic late effects as well as a standardized QoL questionnaire (European Organisation for Research and Treatment of Cancer QLQ-C30). Comparis…

Cancer ResearchState of healthHealth StatusPopulationCohort Studies03 medical and health sciences0302 clinical medicineQuality of lifeSurveys and QuestionnairesHumansMedicineSurvivorsChildeducationSocioeconomic statuseducation.field_of_studyBrain Neoplasmsbusiness.industryConfoundingEditorialsCancermedicine.diseasehumanitiesSocioeconomic FactorsOncology030220 oncology & carcinogenesisCohortQuality of LifeNeurology (clinical)businessPediatric Neuro-Oncology030217 neurology & neurosurgeryCohort studyDemography
researchProduct

Tumour-like presentation of atypical posterior reversible encephalopathy syndrome with prominent brainstem involvement

2020

Typical posterior reversible encephalopathy syndrome (PRES) is a clinical-neuroradiological entity characterised by bilateral white matter oedema, which is usually symmetrical and totally reversible in 2–3 weeks. A 46-year-old man presented with a persistent headache and visual blurring in the right eye. On admission, the clinical examination revealed minimal unsteadiness of gait and elevated blood pressure. A brain MRI showed a hyperintense signal on T2-weighted sequences in the whole brainstem, extended to the spinal cord (C2–C6), the left insula and the right cerebellum. When his blood pressure was controlled, his symptoms gradually improved. The follow-up MRI scan at 3 weeks revealed a …

Malemedicine.medical_specialtyCerebellumNeurologyNifedipinePhysical examination030218 nuclear medicine & medical imagingWhite matterDiagnosis Differential03 medical and health sciences0302 clinical medicineRamiprilmedicineHumansAntihypertensive AgentsUnusual Presentation of More Common Disease/Injuryneuroimagingmedicine.diagnostic_testbusiness.industryneurologyBrain stem/cerebellumDoxazosinPosterior reversible encephalopathy syndromeGeneral MedicineMiddle AgedSpinal cordmedicine.diseaseCalcium Channel BlockersMagnetic Resonance ImagingWhite Matterradiologymedicine.anatomical_structureSettore MED/26 - NeurologiaRadiologyBrainstemPosterior Leukoencephalopathy SyndromeDifferential diagnosisbusinessneuro-oncology030217 neurology & neurosurgeryBrain Stem
researchProduct

Focused Ultrasound in Neuroscience. State of the Art and Future Perspectives

2021

Transcranial MR-guided Focused ultrasound (tcMRgFUS) is a surgical procedure that adopts focused ultrasounds beam towards a specific therapeutic target through the intact skull. The convergence of focused ultrasound beams onto the target produces tissue effects through released energy. Regarding neurosurgical applications, tcMRgFUS has been successfully adopted as a non-invasive procedure for ablative purposes such as thalamotomy, pallidotomy, and subthalamotomy for movement disorders. Several studies confirmed the effectiveness of tcMRgFUS in the treatment of several neurological conditions, ranging from motor disorders to psychiatric disorders. Moreover, using low-frequencies tcMRgFUS sys…

OpinionComputer scienceNeurodegenerative diseaseFocused ultrasoundlcsh:RC321-57103 medical and health sciences0302 clinical medicineneurodegenerative diseaseslcsh:Neurosciences. Biological psychiatry. Neuropsychiatry030304 developmental biologyBlood-brain barriertcMRgFUSLIFU0303 health sciencesEpilepsySettore MED/27 - NeurochirurgiaGeneral NeuroscienceSettore MED/37 - NeuroradiologiaPsychiatric disorderHIFUpsychiatric disordersfocused ultrasoundSettore MED/26 - NeurologiaSettore MED/36 - Diagnostica Per Immagini E RadioterapiaNeuroscienceneuro-oncology030217 neurology & neurosurgeryBrain Sciences
researchProduct

A Spotlight on the Role of Radiomics and Machine-Learning Applications in the Management of Intracranial Meningiomas: A New Perspective in Neuro-Onco…

2022

Background: In recent decades, the application of machine learning technologies to medical imaging has opened up new perspectives in neuro-oncology, in the so-called radiomics field. Radiomics offer new insight into glioma, aiding in clinical decision-making and patients’ prognosis evaluation. Although meningiomas represent the most common primary CNS tumor and the majority of them are benign and slow-growing tumors, a minor part of them show a more aggressive behavior with an increased proliferation rate and a tendency to recur. Therefore, their treatment may represent a challenge. Methods: According to PRISMA guidelines, a systematic literature review was performed. We included selected a…

machine learningradiomicsSettore MED/27 - NeurochirurgiaSpace and Planetary Sciencedeep learningPaleontologymeningiomaneuro-oncologyGeneral Biochemistry Genetics and Molecular BiologyEcology Evolution Behavior and SystematicsLife (Basel, Switzerland)
researchProduct

Fluorescein for resection of high-grade gliomas: A safety study control in a single center and review of the literature

2017

Background: The importance of a complete resection of high-grade gliomas (HGGs) has been highlighted in scientific literature, in order to limit tumor recurrence and above all to improve disease-free survival rates. Several fluorescent biomarkers have been tested to improve intraoperative identification of residual tumor; 5-aminolevulinic acid (5-ALA) and fluorescein sodium (FS) are now starting to play a central role in glioma surgery. We performed a retrospective analysis on 47 patients operated for HGGs. Here we report our preliminary data. Methods: Data of 47 consecutive patients with HGG have been collected in our study (25 males, 22 females; mean age: 60.3 years, range: 27-86 years). …

medicine.medical_specialtySingle CenterResection03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGliomaYELLOW 560 filterMedicinefluorescein sodiumFluoresceinAdverse effectSettore MED/27 - Neurochirurgiabusiness.industrySubtotal ResectionPartial resectionmedicine.diseaseextent of resectionSurgerychemistry5-aminolevulinic acid030220 oncology & carcinogenesisSurgeryNeuro-Oncology: Original ArticleNeurology (clinical)Sodium fluoresceinbusinessNuclear medicinehigh-grade gliomas030217 neurology & neurosurgerySurgical Neurology International
researchProduct